The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of pathohistologic complete remission (pCR) rate on the prediction of long-term prognosis following chemoradiotherapy (XRT) with cetuximab (Cet), capecitabine (CAP), and oxaliplatin (OX; Cet-CAPOX) in patients (pts) with locally advanced rectal cancer (LARC).
T. Liersch
No relevant relationships to disclose
C. Weiss
No relevant relationships to disclose
K. Dellas
No relevant relationships to disclose
M. Hipp
No relevant relationships to disclose
R. Sauer
No relevant relationships to disclose
C. Rödel
Honoraria - Merck KGaA; Roche; Sanofi
Research Funding - Merck KGaA; Roche; Sanofi
D. Arnold
Honoraria - Merck KGaA; Roche; Sanofi
Research Funding - Merck KGaA; Roche; Sanofi